HP
ABVX

HealthInvest Partners’s Abivax ABVX Stock Holding History

HealthInvest Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Buy
58,170
+26,580
+84% +$3.01M 2.09% 22
2026
Q1 		$4.78M Hold
31,590
– – 1.54% 28
2025
Q4 		$4.26M Buy
+31,590
New +$3.45M 1.36% 27

Other funds holding ABVX

NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
SCS
Syquant Capital SAS Paris, France $447M AUM 13.04% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
AI
Atria Investments Charlotte, North Carolina $9.98B AUM 26.5% 1-Year Est. Return

HealthInvest Partners's ABVX Position: Q2 2026 in Review

HealthInvest Partners increased its Abivax (ABVX) stake by 84% in Q2 2026, buying an estimated $3.01M and bringing the position to 58,170 shares worth $7.75M. The position accounts for 2.09% of the portfolio, ranked #22.

HealthInvest Partners first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. 49 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • HealthInvest Partners held 58,170 shares of Abivax worth $7.75M as of Q2 2026.
  • HealthInvest Partners bought 26,580 Abivax shares in Q2 2026, an estimated $3.01M.
  • Abivax made up 2.09% of HealthInvest Partners's portfolio in Q2 2026, its #22 holding.
  • HealthInvest Partners first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • 49 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.